Is tucatinib cytotoxic?

Tucatinib is an oral small molecule tyrosine kinase inhibitor (TKI) that specifically targets HER2 (human epidermal growth factor receptor 2 ).

Tucatinib selectively inhibits the HER2 tyrosine kinase and blocks the conduction of the HER2 signaling pathway, thereby inhibiting the growth and spread of tumor cells. This process mainly affects tumor cells that overexpress HER2, but has relatively little impact on normal cells.

Tucatinib is highly selective for HER2, which means that it can act more precisely on tumor cells that overexpress HER2 while having less effect on normal cells. Therefore, from this perspective, tucatinib has relatively low cytotoxicity.

Although tucatinib mainly acts on tumor cells, it may still cause some side effects during treatment, such as diarrhea, palmoplantar erythema syndrome, nausea, fatigue, etc. These side effects are usually mild and controllable, and mainly affect the patient's physical function and comfort rather than directly causing toxic damage to normal cells.

Multiple clinical trial data show that tucatinib performs well in prolonging progression-free survival (PFS) and overall survival (OS) in patients with HER2 positive breast cancer and colorectal cancer, while having minor and controllable side effects. These data indirectly demonstrate the relatively low cytotoxicity of tucatinib.

It should be noted that any drug may have certain risks and side effects during treatment. Therefore, when using tucatinib, patients should strictly follow the doctor's instructions and pay close attention to their physical condition and adverse reactions. If you have any discomfort or questions, you should consult your doctor and seek help in time.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10519189/